a(CHEBI:"phorbol 13-acetate 12-myristate")

Entity

Name

phorbol 13-acetate 12-myristate

Namespace

chebi

Namespace Version

20180906

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

PMA is a known agonist of PKC, which leads to the activation of the PKC/RAS/RAF/MEK/MAPK pathway that ultimately induces NFkB activation (46–48) PubMed:25331948

PMA is a known agonist of PKC, which leads to the activation of the PKC/RAS/RAF/MEK/MAPK pathway that ultimately induces NFkB activation (46–48) PubMed:25331948

In particular, we monitored RAF phosphorylation following treatment with (-)-nilvadipine and observed that (-)-nilvadipine prevents RAF phosphorylation induced by PMA (Fig. 4, C and D) suggesting that (-)-nilvadipine is impacting a target upstream of RAF PubMed:25331948

As expected, RAF phosphorylation induced by PMA as well as basal RAF phosphorylation were reduced in 7W CHO cells transfected with SYK shRNA confirming a reduction in Syk activity (Fig. 6B). PubMed:25331948

Tyrosine kinases, including Syk and Bruton’s tyrosine kinase (BTK), are activated following PMA treatment (49, 50), act upstream of RAS/RAF (51, 52), and mediate the activation of the NFkB pathway (53). PubMed:25331948

Tyrosine kinases, including Syk and Bruton’s tyrosine kinase (BTK), are activated following PMA treatment (49, 50), act upstream of RAS/RAF (51, 52), and mediate the activation of the NFkB pathway (53). PubMed:25331948